Trevena Inc. (TRVN) NASDAQ

$0.26 0 (0.27%)

Market Cap: $44.22M

As of 08/15/22 11:05 AM EDT. Market open.

(TRVN)

Trevena Inc. (TRVN) NASDAQ

$0.26 0 (0.27%)

Market Cap: $44.22M

As of 08/15/22 11:05 AM EDT. Market open.

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK™ (oliceridine) injection, indicated inadults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are ... read more

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK™ (oliceridine) injection, indicated inadults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company also has four novel and differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, and TRV027 for acute lung injury / abnormal blood clotting in COVID-19 patients. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new approach to treating a variety of CNS disorders. read less

COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
Carrie Bourdow
Full Time Employees
25
CEO Compensation (Base)
$536,667
CEO Compensation (Total)
$2.81M
URL
Address
955 Chesterbrook Blvd Ste 110, Pennsylvania, Chesterbrook, 19087-5627.
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
Carrie Bourdow
Full Time Employees
25
CEO Compensation (Base)
$536,667
CEO Compensation (Total)
$2.81M
Address
955 Chesterbrook Blvd Ste 110, Pennsylvania, Chesterbrook, 19087-5627.
PRICE CHART
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
KEY STATS
Open
$0.25
Previous Close
$0.25
Days Range
$0.24 - $0.26
52 week range
$0.18 - $1.40
Volume
204,657
Avg. Volume (30 days)
1,433,959
Market Cap
$44.22M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
173,681,085
Open
$0.25
Previous Close
$0.25
Days Range
$0.24 - $0.26
52 week range
$0.18 - $1.40
Volume
204,657
Avg. Volume (30 days)
1,433,959
Market Cap
$44.22M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
173,681,085

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR TREVENA INC
Owner Relationship Date Transaction Cost # Shares Value($) Total Shares Form 4
Shin Barry SVP, CFO Jun 28, 2022 Sale $0.41 31,785 13,032 873,056 Jun 29, 2022, 05:12 PM
Bourdow Carrie L. President & CEO Dec 17, 2021 Option Exercise $0.70 33,546 23,482 2,424,403 Dec 21, 2021, 04:17 PM
Demitrack Mark SVP, Chief Medical Officer Dec 17, 2021 Option Exercise $0.70 12,408 8,686 791,172 Dec 21, 2021, 04:16 PM
Yoder Robert T SVP, Chief Business Officer Dec 17, 2021 Option Exercise $0.70 9,711 6,798 565,205 Dec 21, 2021, 04:11 PM
Shin Barry SVP, CFO Dec 17, 2021 Option Exercise $0.70 14,216 9,951 904,841 Dec 21, 2021, 04:10 PM
Demitrack Mark SVP, Chief Medical Officer Dec 06, 2021 Option Exercise $0.65 30,601 19,891 803,580 Dec 08, 2021, 04:17 PM
Yoder Robert T SVP, Chief Business Officer Dec 06, 2021 Option Exercise $0.65 22,950 14,917 574,916 Dec 08, 2021, 04:17 PM
Shin Barry SVP, CFO & CCO Dec 06, 2021 Option Exercise $0.65 34,408 22,365 919,057 Dec 08, 2021, 04:16 PM
Bourdow Carrie L. President & CEO Dec 06, 2021 Option Exercise $0.65 93,561 60,815 2,457,949 Dec 08, 2021, 04:16 PM
Bourdow Carrie L. President & CEO Jun 28, 2021 Buy $1.79 56,200 100,542 1,301,510 Jun 28, 2021, 05:33 PM
Shin Barry Chief Financial Officer Jun 25, 2021 Option Exercise $1.96 24,635 48,285 535,965 Jun 25, 2021, 05:49 PM
Applebaum Scott CLCO; SVP, Regulatory Affairs Feb 10, 2021 Option Exercise $2.85 21,178 60,357 344,022 Feb 12, 2021, 04:17 PM
Bourdow Carrie L. President & CEO Dec 07, 2020 Option Exercise $2.27 151,684 344,323 1,245,310 Dec 31, 2020, 04:52 PM
Yoder Robert T Sr VP Chief Commercial Officer Dec 07, 2020 Option Exercise $2.27 36,688 83,282 216,566 Dec 09, 2020, 04:43 PM
Demitrack Mark Sr. VP & Chief Medical Officer Dec 07, 2020 Option Exercise $2.27 48,557 110,224 271,481 Dec 09, 2020, 04:38 PM
Bourdow Carrie L. President & CEO Dec 07, 2020 Option Exercise $2.27 132,934 301,760 792,960 Dec 09, 2020, 04:37 PM
Shin Barry Chief Financial Officer Dec 07, 2020 Option Exercise $2.27 41,861 95,024 403,600 Dec 09, 2020, 04:35 PM
Shin Barry Chief Financial Officer Jun 25, 2020 Option Exercise $1.72 23,539 40,487 445,461 Jun 29, 2020, 07:49 PM
Yoder Robert T Sr. VP, Chief Business Officer Dec 02, 2019 Option Exercise $0.69 6,874 4,735 86,254 Dec 04, 2019, 05:48 PM
Demitrack Mark Sr. VP & Chief Medical Officer Dec 02, 2019 Option Exercise $0.69 8,982 6,188 107,038 Dec 04, 2019, 05:47 PM
Bourdow Carrie L. President and CEO Dec 02, 2019 Option Exercise $0.69 17,804 12,265 268,894 Dec 04, 2019, 05:46 PM
Demitrack Mark Sr VP & Chief Medical Officer Jun 03, 2019 Option Exercise $1.17 8,980 10,507 116,020 Jun 04, 2019, 04:53 PM
Hamill John P. VP Fin,Princ Fin&Acct Officer Jun 03, 2019 Option Exercise $1.17 5,516 6,454 82,234 Jun 04, 2019, 04:52 PM
Hamill John P. VP Fin,Princ Fin&Acct Officer May 31, 2019 Buy $1.16 7,500 8,700 87,750 Jun 04, 2019, 04:52 PM
Yoder Robert T Sr. VP, Chief Business Officer Jun 03, 2019 Option Exercise $1.17 6,872 8,040 93,128 Jun 04, 2019, 04:51 PM
Bourdow Carrie L. President and CEO Jun 03, 2019 Option Exercise $1.17 17,802 20,828 286,698 Jun 04, 2019, 04:49 PM
GOWEN MAXINE President & CEO Feb 01, 2019 Buy $1.02 50,000 51,000 54,000 Feb 05, 2019, 04:59 PM
Bourdow Carrie L. President and CEO Feb 01, 2019 Option Exercise $1.02 50,000 51,000 304,500 Feb 05, 2019, 08:41 AM
MOULDER LEON O JR Director Feb 01, 2019 Buy $1.02 100,000 102,000 100,000 Feb 04, 2019, 09:01 AM
Habib Yacoub SVP, Bus Dev & Corp Planning Mar 22, 2018 Sale $1.76 5,000 8,800 0 Mar 23, 2018, 05:16 PM
GOWEN MAXINE President & CEO Feb 23, 2017 Option Exercise $0.68 110,403 75,295 126,903 Feb 27, 2017, 08:34 AM
Lark Michael W. Sr. VP, Research & CSO Feb 10, 2017 Option Exercise $0.68 12,815 8,740 98,460 Feb 14, 2017, 05:20 PM
Lark Michael W. Sr. VP, Research & CSO Feb 10, 2017 Sale $8.00 23,699 189,592 74,761 Feb 14, 2017, 05:20 PM
Bourdow Carrie L. SVP, Chief Commercial Officer Nov 09, 2016 Buy $4.34 4,000 17,360 4,500 Nov 10, 2016, 06:12 PM
GOWEN MAXINE President & CEO Nov 07, 2016 Buy $4.10 12,500 51,250 16,500 Nov 09, 2016, 05:37 PM
Habib Yacoub SVP, Bus Dev & Corp Planning Nov 07, 2016 Buy $4.12 5,000 20,600 5,000 Nov 09, 2016, 05:36 PM
GOWEN MAXINE President & CEO May 27, 2016 Buy $7.08 14,084 99,715 293,109 May 31, 2016, 05:34 PM
GOWEN MAXINE President & CEO May 26, 2016 Buy $7.20 4,000 28,800 4,000 May 31, 2016, 05:34 PM
GOWEN MAXINE President & CEO May 26, 2016 Buy $7.19 4,000 28,760 279,025 May 31, 2016, 05:34 PM
Soergel David Sr. VP,Clinical Dev. & CMO Dec 10, 2015 Sale $10.55 27,217 287,139 1,750 Dec 11, 2015, 05:17 PM
Limongelli John M Sr. VP,General Counsel & Secy Dec 12, 2014 Buy $4.14 3,000 12,420 12,000 Dec 15, 2014, 05:00 PM
MOULDER LEON O JR Director Dec 09, 2014 Buy $3.96 30,200 119,592 30,200 Dec 10, 2014, 08:39 PM
MOULDER LEON O JR Director Dec 10, 2014 Buy $4.06 19,800 80,388 50,000 Dec 10, 2014, 08:39 PM
Soergel David Sr. VP, Clinical Development Dec 10, 2014 Buy $4.00 1,250 5,000 28,967 Dec 10, 2014, 08:37 PM
Soergel David Sr. VP, Clinical Development Dec 09, 2014 Buy $3.97 500 1,985 27,717 Dec 10, 2014, 08:37 PM
Limongelli John M Sr. VP,General Counsel & Secy Dec 10, 2014 Buy $4.00 9,000 36,000 9,000 Dec 10, 2014, 06:07 PM
Cuca Roberto Sr. VP and CFO Dec 10, 2014 Buy $4.00 25,000 100,000 25,000 Dec 10, 2014, 06:05 PM
Yanni Barbara Director Dec 10, 2014 Buy $4.00 1,250 5,000 1,250 Dec 10, 2014, 06:03 PM
DOUGHERTY MICHAEL R Director Dec 10, 2014 Buy $4.00 7,000 28,000 7,000 Dec 10, 2014, 06:01 PM
Soergel David Sr. VP, Clinical Development Dec 10, 2014 Buy $4.00 1,250 5,000 28,467 Dec 10, 2014, 05:59 PM
Lark Michael W. Sr. VP, Research & CSO Dec 10, 2014 Buy $4.00 5,000 20,000 85,645 Dec 10, 2014, 05:56 PM
GOWEN MAXINE President & CEO Dec 10, 2014 Buy $4.00 8,000 32,000 326,025 Dec 10, 2014, 05:54 PM
Alta Partners VIII, L.P. 10% Owner Dec 10, 2014 Buy $4.00 500,000 2,000,000 4,390,262 Dec 10, 2014, 05:51 PM
New Enterprise Associates 12, Limited Partnership 10% Owner Dec 10, 2014 Buy $4.00 1,000,000 4,000,000 4,811,691 Dec 10, 2014, 12:13 PM
Deegan Rosamond Sr VP, Bus Dev & Operations Sep 29, 2014 Sale $7.00 44 308 31,105 Oct 01, 2014, 04:48 PM
Polaris Venture Management Co. V, L.L.C. 10% Owner Aug 14, 2014 Sale $6.04 36,702 221,680 3,637,115 Aug 18, 2014, 04:30 PM
Polaris Venture Management Co. V, L.L.C. 10% Owner Aug 13, 2014 Sale $6.12 5,700 34,884 3,672,530 Aug 15, 2014, 04:30 PM
GOWEN MAXINE President & CEO Apr 23, 2014 Option Exercise $0.68 124,477 84,893 318,025 May 15, 2014, 09:37 PM
Forest Laboratories Holdings Ltd 10% Owner Feb 05, 2014 Buy $7.00 428,571 2,999,997 3,393,466 Feb 07, 2014, 01:14 PM
New Enterprise Associates 12, Limited Partnership 10% Owner Feb 05, 2014 Buy $7.00 472,410 3,306,870 3,811,691 Feb 07, 2014, 12:16 PM
Polaris Venture Management Co. V, L.L.C. 10% Owner Feb 05, 2014 Buy $7.00 472,405 3,306,835 3,811,682 Feb 07, 2014, 12:06 PM
HealthCare Ventures VIII, L.P. 10% Owner Feb 05, 2014 Buy $7.00 297,058 2,079,406 2,446,251 Feb 07, 2014, 12:02 PM
Alta Partners VIII, L.P. 10% Owner Feb 05, 2014 Buy $7.00 472,410 3,306,870 3,890,262 Feb 07, 2014, 11:57 AM
Load More Insider Transactions
Buy Sale Option Exercise
Owner Relationship Date Value($)
Shin Barry SVP, CFO 06/28/2022 13,032
Bourdow Carrie L. President & CEO 12/17/2021 23,482
Demitrack Mark SVP, Chief Medical Officer 12/17/2021 8,686
Yoder Robert T SVP, Chief Business Officer 12/17/2021 6,798
Shin Barry SVP, CFO 12/17/2021 9,951
Demitrack Mark SVP, Chief Medical Officer 12/06/2021 19,891
Yoder Robert T SVP, Chief Business Officer 12/06/2021 14,917
Shin Barry SVP, CFO & CCO 12/06/2021 22,365
Bourdow Carrie L. President & CEO 12/06/2021 60,815
Bourdow Carrie L. President & CEO 06/28/2021 100,542
Shin Barry Chief Financial Officer 06/25/2021 48,285
Applebaum Scott CLCO; SVP, Regulatory Affairs 02/10/2021 60,357
Bourdow Carrie L. President & CEO 12/07/2020 344,323
Yoder Robert T Sr VP Chief Commercial Officer 12/07/2020 83,282
Demitrack Mark Sr. VP & Chief Medical Officer 12/07/2020 110,224
Bourdow Carrie L. President & CEO 12/07/2020 301,760
Shin Barry Chief Financial Officer 12/07/2020 95,024
Shin Barry Chief Financial Officer 06/25/2020 40,487
Yoder Robert T Sr. VP, Chief Business Officer 12/02/2019 4,735
Demitrack Mark Sr. VP & Chief Medical Officer 12/02/2019 6,188
Bourdow Carrie L. President and CEO 12/02/2019 12,265
Demitrack Mark Sr VP & Chief Medical Officer 06/03/2019 10,507
Hamill John P. VP Fin,Princ Fin&Acct Officer 06/03/2019 6,454
Hamill John P. VP Fin,Princ Fin&Acct Officer 05/31/2019 8,700
Yoder Robert T Sr. VP, Chief Business Officer 06/03/2019 8,040
Bourdow Carrie L. President and CEO 06/03/2019 20,828
GOWEN MAXINE President & CEO 02/01/2019 51,000
Bourdow Carrie L. President and CEO 02/01/2019 51,000
MOULDER LEON O JR Director 02/01/2019 102,000
Habib Yacoub SVP, Bus Dev & Corp Planning 03/22/2018 8,800
GOWEN MAXINE President & CEO 02/23/2017 75,295
Lark Michael W. Sr. VP, Research & CSO 02/10/2017 8,740
Lark Michael W. Sr. VP, Research & CSO 02/10/2017 189,592
Bourdow Carrie L. SVP, Chief Commercial Officer 11/09/2016 17,360
GOWEN MAXINE President & CEO 11/07/2016 51,250
Habib Yacoub SVP, Bus Dev & Corp Planning 11/07/2016 20,600
GOWEN MAXINE President & CEO 05/27/2016 99,715
GOWEN MAXINE President & CEO 05/26/2016 28,800
GOWEN MAXINE President & CEO 05/26/2016 28,760
Soergel David Sr. VP,Clinical Dev. & CMO 12/10/2015 287,139
Limongelli John M Sr. VP,General Counsel & Secy 12/12/2014 12,420
MOULDER LEON O JR Director 12/09/2014 119,592
MOULDER LEON O JR Director 12/10/2014 80,388
Soergel David Sr. VP, Clinical Development 12/10/2014 5,000
Soergel David Sr. VP, Clinical Development 12/09/2014 1,985
Limongelli John M Sr. VP,General Counsel & Secy 12/10/2014 36,000
Cuca Roberto Sr. VP and CFO 12/10/2014 100,000
Yanni Barbara Director 12/10/2014 5,000
DOUGHERTY MICHAEL R Director 12/10/2014 28,000
Soergel David Sr. VP, Clinical Development 12/10/2014 5,000
Lark Michael W. Sr. VP, Research & CSO 12/10/2014 20,000
GOWEN MAXINE President & CEO 12/10/2014 32,000
Alta Partners VIII, L.P. 10% Owner 12/10/2014 2,000,000
New Enterprise Associates 12, Limited Partnership 10% Owner 12/10/2014 4,000,000
Deegan Rosamond Sr VP, Bus Dev & Operations 09/29/2014 308
Polaris Venture Management Co. V, L.L.C. 10% Owner 08/14/2014 221,680
Polaris Venture Management Co. V, L.L.C. 10% Owner 08/13/2014 34,884
GOWEN MAXINE President & CEO 04/23/2014 84,893
Forest Laboratories Holdings Ltd 10% Owner 02/05/2014 2,999,997
New Enterprise Associates 12, Limited Partnership 10% Owner 02/05/2014 3,306,870
Polaris Venture Management Co. V, L.L.C. 10% Owner 02/05/2014 3,306,835
HealthCare Ventures VIII, L.P. 10% Owner 02/05/2014 2,079,406
Alta Partners VIII, L.P. 10% Owner 02/05/2014 3,306,870
Load More Insider Transactions
CHANGE IN SHARES OUTSTANDING
STOCK BUYBACKS
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
06/30/2022
03/31/2022
0%
1Q
06/30/2022
12/31/2021
1.37%
2Q
06/30/2022
09/30/2021
1.67%
3Q
06/30/2022
06/30/2021
2.21%
4Q
06/30/2022
03/31/2021
3.12%
5Q
06/30/2022
12/31/2020
29.70%
6Q
06/30/2022
09/30/2020
40.97%
7Q
Load More

Period of Report: 06/30/2022

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
03/31/2022
0%
1Q
12/31/2021
1.37%
2Q
09/30/2021
1.67%
3Q
06/30/2021
2.21%
4Q
03/31/2021
3.12%
5Q
12/31/2020
29.70%
6Q
09/30/2020
40.97%
7Q
Load More